Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells

Background: Light chain research is hampered by lack of mammalian cell lines producing human light chains (FLC). Therefore, we used heterohybridoma (HH) technology to produce clones making FLC thereby providing tools to study light chain behavior. Methods: Marrow CD138+ cells from patients with mult...

Full description

Saved in:
Bibliographic Details
Main Authors: P. Zhou, X. Ma, S. Scalia, D. Toskic, X. Wu, T. Fogaren, Nancy Coady Lyons, Luis del Pozo-Yauner, R.L. Comenzo
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Biochemistry and Biophysics Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405580825001049
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850246239863439360
author P. Zhou
X. Ma
S. Scalia
D. Toskic
X. Wu
T. Fogaren
Nancy Coady Lyons
Luis del Pozo-Yauner
R.L. Comenzo
author_facet P. Zhou
X. Ma
S. Scalia
D. Toskic
X. Wu
T. Fogaren
Nancy Coady Lyons
Luis del Pozo-Yauner
R.L. Comenzo
author_sort P. Zhou
collection DOAJ
description Background: Light chain research is hampered by lack of mammalian cell lines producing human light chains (FLC). Therefore, we used heterohybridoma (HH) technology to produce clones making FLC thereby providing tools to study light chain behavior. Methods: Marrow CD138+ cells from patients with multiple myeloma (MM) and polyclonal gammopathy (PG) were selected, fused with B5-6 T cells and cultured in hypoxanthine-aminopterin-thymidine medium (HAT). HH clones were selected based on ELISA for human immunoglobulins and flow cytometry for intracellular (IC) FLC. We compared marrow cell counts and HH yields by diagnosis, evaluated clones making only FLC by flow and by dimer/monomer (D/M) ratios in vitro and in vivo, and sequenced FLC genes with RT-PCR. Results: Marrows from 13 patients with active disease, 10 MM and 3 PG, were no different in mononuclear or CD138-selected cell counts. HH FLC clones (7 λ, 1 κ) were obtained from 5/10 MM and 2/3 PG; one PG case produced 2 HH FLC clones (one λ and one κ). Of the 10 MM cases, 8 had high risk cytogenetic features and 4 of the 8 produced HH clones while of the 3 PG cases 2 had negative cytogenetics and 1 had loss of IgH identified and produced an HH clone. Mononuclear (MNC) and CD138-selected cell numbers were markedly higher in the samples that enabled productive fusions. Median MFI for the 8 HH clones by IC flow for FLC was 9849 (range, 5344–27451) and median percentage of cells IC positive was 88 % (69–95). Medians of in vitro and in vivo FLC production were 47 μg/mL (9–80) per million cells after 2 days of culture and 66.4 μg/mL (16–1100) in NOD-SCID γ (NSG) mice 14 days after intraperitoneal (IP) implants of 2 × 106 HH cells. Dimer/monomer ratio medians were 0.575 (0.08–0.939) in vitro and 0.91 (0.82–2.7) in vivo, values that were correlated (R2 = 0.565) by two-tailed paired t-test with P < 0.05. Conclusions: B5-6 T HH producing human FLC were obtained from 50 % of MM and PG cases. High numbers of MNC and CD138+ cells enabled productive fusions. The HH clones produced FLC with easily appreciated dimers and monomers in vitro and in vivo. With IP in vivo implants after 2 weeks more dimers were seen than in short term cultures in vitro. These HH clones will be made available for study of FLC metabolism and testing of therapeutics designed to abrogate FLC production or enable FLC clearance in vivo.
format Article
id doaj-art-66b80802e8b548e18485d2a2224376b3
institution OA Journals
issn 2405-5808
language English
publishDate 2025-06-01
publisher Elsevier
record_format Article
series Biochemistry and Biophysics Reports
spelling doaj-art-66b80802e8b548e18485d2a2224376b32025-08-20T01:59:14ZengElsevierBiochemistry and Biophysics Reports2405-58082025-06-014210201710.1016/j.bbrep.2025.102017Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cellsP. Zhou0X. Ma1S. Scalia2D. Toskic3X. Wu4T. Fogaren5Nancy Coady Lyons6Luis del Pozo-Yauner7R.L. Comenzo8Tufts Medicine Myeloma and Amyloid Program, USATufts Medicine Myeloma and Amyloid Program, USATufts Medicine Myeloma and Amyloid Program, USATufts Medicine Myeloma and Amyloid Program, USADivision of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, USATufts Medicine Myeloma and Amyloid Program, USA; Division of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, USATufts Medicine Myeloma and Amyloid Program, USA; Division of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, USADepartment of Pathology, University of South Alabama, Mobile, AL, USATufts Medicine Myeloma and Amyloid Program, USA; Division of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA, USA; Corresponding author. Tufts Medical Center, Box 826, 800 Washington Street, Boston, MA, 02111, USA.Background: Light chain research is hampered by lack of mammalian cell lines producing human light chains (FLC). Therefore, we used heterohybridoma (HH) technology to produce clones making FLC thereby providing tools to study light chain behavior. Methods: Marrow CD138+ cells from patients with multiple myeloma (MM) and polyclonal gammopathy (PG) were selected, fused with B5-6 T cells and cultured in hypoxanthine-aminopterin-thymidine medium (HAT). HH clones were selected based on ELISA for human immunoglobulins and flow cytometry for intracellular (IC) FLC. We compared marrow cell counts and HH yields by diagnosis, evaluated clones making only FLC by flow and by dimer/monomer (D/M) ratios in vitro and in vivo, and sequenced FLC genes with RT-PCR. Results: Marrows from 13 patients with active disease, 10 MM and 3 PG, were no different in mononuclear or CD138-selected cell counts. HH FLC clones (7 λ, 1 κ) were obtained from 5/10 MM and 2/3 PG; one PG case produced 2 HH FLC clones (one λ and one κ). Of the 10 MM cases, 8 had high risk cytogenetic features and 4 of the 8 produced HH clones while of the 3 PG cases 2 had negative cytogenetics and 1 had loss of IgH identified and produced an HH clone. Mononuclear (MNC) and CD138-selected cell numbers were markedly higher in the samples that enabled productive fusions. Median MFI for the 8 HH clones by IC flow for FLC was 9849 (range, 5344–27451) and median percentage of cells IC positive was 88 % (69–95). Medians of in vitro and in vivo FLC production were 47 μg/mL (9–80) per million cells after 2 days of culture and 66.4 μg/mL (16–1100) in NOD-SCID γ (NSG) mice 14 days after intraperitoneal (IP) implants of 2 × 106 HH cells. Dimer/monomer ratio medians were 0.575 (0.08–0.939) in vitro and 0.91 (0.82–2.7) in vivo, values that were correlated (R2 = 0.565) by two-tailed paired t-test with P < 0.05. Conclusions: B5-6 T HH producing human FLC were obtained from 50 % of MM and PG cases. High numbers of MNC and CD138+ cells enabled productive fusions. The HH clones produced FLC with easily appreciated dimers and monomers in vitro and in vivo. With IP in vivo implants after 2 weeks more dimers were seen than in short term cultures in vitro. These HH clones will be made available for study of FLC metabolism and testing of therapeutics designed to abrogate FLC production or enable FLC clearance in vivo.http://www.sciencedirect.com/science/article/pii/S2405580825001049Immunoglobulin light chainsHeterohybridomasCD138Plasma cells
spellingShingle P. Zhou
X. Ma
S. Scalia
D. Toskic
X. Wu
T. Fogaren
Nancy Coady Lyons
Luis del Pozo-Yauner
R.L. Comenzo
Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells
Biochemistry and Biophysics Reports
Immunoglobulin light chains
Heterohybridomas
CD138
Plasma cells
title Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells
title_full Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells
title_fullStr Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells
title_full_unstemmed Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells
title_short Heterohybridomas producing human immunoglobulin light chains using CD138-selected bone marrow cells
title_sort heterohybridomas producing human immunoglobulin light chains using cd138 selected bone marrow cells
topic Immunoglobulin light chains
Heterohybridomas
CD138
Plasma cells
url http://www.sciencedirect.com/science/article/pii/S2405580825001049
work_keys_str_mv AT pzhou heterohybridomasproducinghumanimmunoglobulinlightchainsusingcd138selectedbonemarrowcells
AT xma heterohybridomasproducinghumanimmunoglobulinlightchainsusingcd138selectedbonemarrowcells
AT sscalia heterohybridomasproducinghumanimmunoglobulinlightchainsusingcd138selectedbonemarrowcells
AT dtoskic heterohybridomasproducinghumanimmunoglobulinlightchainsusingcd138selectedbonemarrowcells
AT xwu heterohybridomasproducinghumanimmunoglobulinlightchainsusingcd138selectedbonemarrowcells
AT tfogaren heterohybridomasproducinghumanimmunoglobulinlightchainsusingcd138selectedbonemarrowcells
AT nancycoadylyons heterohybridomasproducinghumanimmunoglobulinlightchainsusingcd138selectedbonemarrowcells
AT luisdelpozoyauner heterohybridomasproducinghumanimmunoglobulinlightchainsusingcd138selectedbonemarrowcells
AT rlcomenzo heterohybridomasproducinghumanimmunoglobulinlightchainsusingcd138selectedbonemarrowcells